IOB - Delayed Quote DKK

Zealand Pharma A/S (0NZU.IL)

427.00

+4.35

+(1.03%)

As of 2:20:48 PM GMT+1. Market Open.

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes. The ZUPREME-2 trial is designed to evaluate three doses of petrelintide up to 9 mg over 28 weeks of treatment. Completion of enrollment in ZUPREME-2 is expected in the seco

GlobeNewswire 4 days ago

ZLDPF
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma’s next

GlobeNewswire 5 days ago

ZLDPF
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or relat

GlobeNewswire 8 days ago

ZLDPF
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs for 2025 (the “LTIP”) for Zealand

GlobeNewswire 8 days ago

ZLDPF
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 20 days ago

RGEN

ZEAL.CO
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end

GlobeNewswire 27 days ago

ZLDPF
Resolutions from Zealand Pharma's Annual General Meeting 2025

Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual Ge

GlobeNewswire last month

ZLDPF
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 24 March 2025, Van Herk Inv

GlobeNewswire last month

ZLDPF
Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal value of DKK 1

GlobeNewswire last month

ZLDPF
Enrolment concludes in Zealand’s Phase IIb obesity therapy trial

The study is designed to compare five doses of the one-time-a-week subcutaneous therapy against a placebo.

Clinical Trials Arena last month

ZEAL.CO
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

Pharma Voice last month

ROG.SW

ZEAL.CO
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes in the first half of 2025. Copenhagen

GlobeNewswire last month

ZLDPF
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.

Zacks last month

ROG.SW

NVO

ARVN
High Growth Tech Stocks in Europe to Watch This March 2025

Amidst a backdrop of global trade policy uncertainty and mixed economic signals, the European market has shown resilience, with Germany's DAX Index rising by over 2% despite broader concerns impacting investor sentiment. As the European Central Bank adjusts its monetary policies to address inflation and growth challenges, investors are keeping an eye on high-growth tech stocks that can capitalize on increased infrastructure spending and innovation-driven opportunities.

Simply Wall St. last month

NORDH.OL

JY0.F

ZLDPF
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.

Zacks last month

ROG.SW

NVO

ZEAL.CO
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Zacks last month

ROG.SW

NVO

ZEAL.CO
Roche, Zealand sign deal: What it means for weight loss drug space

Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination Co-Hosts Julie Hyman and Josh Lipton to examine what the deal means for the pair of pharmaceutical companies and competitors like Eli Lilly (LLY) and Novo Nordisk (NVO). To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video last month

RHHBF

RHHBY

RHHVF
Novo Nordisk, Starbucks shares slumping: Trending Tickers

Wealth host Brad Smith discusses some of Wednesday's trending stocks. Novo Nordisk (NVO) stock is sinking after European drugmaker Roche (ROG.SW) reached a deal with Zealand Pharma (ZEAL.CO) to develop a weight loss drug, which is expected to close in the second quarter of this year. Starbucks (SBUX) shares are sliding just ahead of its annual shareholder meeting, where CEO Brian Nichols' $96 million pay package will be scrutinized. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video last month

ZLDPF

NONOF

NVO
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%

Roche inked a new deal in the obesity space, giving Novo Nordisk more competition in its own backyard.

Yahoo Finance last month

NONOF

NVO

ZLDPF
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Roche's stock rallied in Europe, while Zealand surged nearly 40%.

The Wall Street Journal last month

LLY

NONOF

NVO

Performance Overview

Return	0NZU.IL	OMX Copenhagen 25 Index (^OMXC25)
YTD	-40.02%	-9.72%
1-Year	-30.97%	-15.68%
3-Year	+456.24%	-7.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zealand Pharma A/S (0NZU.IL)

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Resolutions from Zealand Pharma's Annual General Meeting 2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Enrolment concludes in Zealand’s Phase IIb obesity therapy trial

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

High Growth Tech Stocks in Europe to Watch This March 2025

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Roche, Zealand sign deal: What it means for weight loss drug space

Novo Nordisk, Starbucks shares slumping: Trending Tickers

Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%

Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal

Performance Overview